Journal
CNS SPECTRUMS
Volume 19, Issue 5, Pages 374-381Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852913000849
Keywords
schizophrenia; hostility; aggression; antipsychotics
Categories
Funding
- Alexza
- Alkermes
- Bristol-Myers Squibb
- Eli Lilly
- Envivo
- Forest
- Genentech
- Janssen
- Lundbeck
- Merck
- Mylan
- Novartis
- Noven
- Otsuka
- Pfizer
- Reckitt Benckiser
- Sunovion
- AstraZeneca
Ask authors/readers for more resources
Introduction. Aggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia. Methods. We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score >= 2) at baseline. Results. The primary analysis of hostility indicated an effect of difference between treatments (F-4,F-1487 = 7.78, P < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6. Discussion. Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride. Conclusion. Olanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available